^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Breast Cancer
    Drug:Zepzelca (lurbinectedin) (Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

    Excerpt:
    ...- Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)...
    Trial ID:
    NCT01525589
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Open
    Title:

    Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

    Published date:
    08/28/2022
    Excerpt:
    This phase II basket multitumor trial (NCT02454972) evaluated lurbinectedin 3.2 mg/m2 1-h intravenous infusion every 3 weeks in a cohort of 21 patients with pretreated germline BRCA1/2 breast cancer....This phase II study met its primary endpoint and showed activity of lurbinectedin in germline BRCA1/2 breast cancer. Lurbinectedin showed a predictable and manageable safety profile.
    DOI:
    10.1016/j.esmoop.2022.100571
    Trial ID:
    NCT02454972
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Lurbinectedin in patients with pretreated BRCA1/2-associated metastatic breast cancer: Results from a phase II basket study

    Published date:
    05/26/2022
    Excerpt:
    Lurbinectedin was active in both BRCA mutations: four PRs in 11 pts (36.4%) in BRCA2 and two PRs in 10 pts (20.0%) in BRCA1. This phase II study met its primary endpoint and confirmed the activity of L in pretreated BRCA1/2-associated breast cancer pts.
    DOI:
    10.1200/JCO.2022.40.16_suppl.1092
    Trial ID:
    NCT02454972